Conduct Phase III CT : CDSCO panel tells AstraZeneca for anticancer drug Olaparib Film coated Tablet
New Delhi: The Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the drug major AstraZeneca to conduct the Phase III clinical trial of Olaprib film-coated Tablets 100mg/150mg for the additional indication as in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer.
Olaparib belongs to a class of drugs called Antineoplastics, PARP Inhibitors. Olaparibis indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Olaparib inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination.
At the recent SEC meeting for Oncology and Hematology held on 23rd of February 2023, the expert panel reviewed the proposal presented by the drug major AstraZeneca for importing & marketing of the drug Olaparib film-coated Tablets 100mg/150mg for an additional indication as “In Combination with Abiraterone and Prednisone or Prednisolone is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer”alongwith CT waiver justification and some global clinical trial data.
"The firm should conduct a Phase III clinical trial for the proposed indication. The firm should submit Phase III clinical trial protocol for further review by the committee."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.